Carfilzomib, Daratumumab, and Dexamethasone (KdD) Vs Carfilzomib and Dexamethasone (Kd) for Relapsed/Refractory Multiple Myeloma (RRMM) in the Phase 3 Candor Study: Subgroup Analysis According to Renal Functioning

被引：0

作者：

Dimopoulos, Meletios Athanasios ^{[1
]}

Landgren, Ola ^{[2
]}

Siegel, David S. ^{[3
]}

Grosicki, Sebastian ^{[4
]}

Oriol, Albert ^{[5
,6
]}

Najdi, Rani ^{[7
]}

Li, Chuang ^{[7
]}

Mezzi, Khalid ^{[7
]}

Shu, Natalie ^{[8
]}

Quach, Hang ^{[9
]}

机构：

[1] Natl & Kapodistrian Univ Athens, Dept Clin Therapeut, Athens, Greece

[2] Univ Miami, Myeloma Div, Sylvester Comprehens Canc Ctr, Miami, FL USA

[3] Hackensack Univ, Med Ctr, Multiple Myeloma Div, Hackensack, NJ USA

[4] Med Univ Silesia, Fac Hlth Sci, Dept Hematol & Canc Prevent, Katowice, Poland

[5] Hosp Badalona Germans Trias & Pujol, Catalan Inst Oncol, Badalona, Spain

[6] Hosp Badalona Germans Trias & Pujol, Josep Carreras Inst, Badalona, Spain

[7] Amgen Inc, Thousand Oaks, CA USA

[8] Paraxel, Chengdu, Peoples R China

[9] St Vincents Hosp Melbourne, East Melbourne, Australia

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-190726

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：4

共 50 条

[21] A Phase 3 Study of Carfilzomib and Dexamethasone (Kd) in Patients With Relapsed and Refractory Multiple Myeloma (MM) in China
Du, Juan
Fang, Baijun
Li, Jian
Jin, Jie
Wang, Shunqing
Zou, Dehui
Cai, Zhen
Wang, Hongxiang
Hu, Jianda
Li, Wei
Fu, Chengcheng
Shao, Zonghong
Xia, Zhongjun
Liu, Peng
Niu, Ting
Tang, En-Tzu
Kimball, Amy
Hou, Jian
Chen, Wenming
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E267 - E268
[22] A comprehensive overview of daratumumab and carfilzomib and the recently approved daratumumab, carfilzomib and dexamethasone regimen in relapsed/refractory multiple myeloma
Richard, Shambavi
Jagannath, Sundar
Cho, Hearn Jay
Parekh, Samir
Madduri, Deepu
Richter, Joshua
Chari, Ajai
EXPERT REVIEW OF HEMATOLOGY, 2021, 14 (01) : 31 - 45
[23] Carfilzomib–dexamethasone vs bortezomib–dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR
W-J Chng
H Goldschmidt
M A Dimopoulos
P Moreau
D Joshua
A Palumbo
T Facon
H Ludwig
L Pour
R Niesvizky
A Oriol
L Rosiñol
A Suvorov
G Gaidano
T Pika
K Weisel
V Goranova-Marinova
H H Gillenwater
N Mohamed
S Feng
S Aggarwal
R Hájek
Leukemia, 2017, 31 : 1368 - 1374
[24] Economic Evaluation of Adding Daratumumab to Carfilzomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma
Yi, Lidan
Liu, Qiao
Tan, Chongqing
Wan, Xiaomin
Luo, Xia
Li, Yinbo
Li, Haiying
Zeng, Xiaohui
RISK MANAGEMENT AND HEALTHCARE POLICY, 2024, 17 : 2829 - 2837
[25] Isatuximab Plus Carfilzomib and Dexamethasone Versus Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma Patients with Renal Impairment: Ikema Subgroup Analysis
Capra, Marcelo
Martin, Thomas, III
Moreau, Philippe
Baker, Ross
Pour, Ludek
Min, Chang-Ki
Leleu, Xavier
Mohty, Mohamad
Segura, Marta Reinoso
Turgut, Mehmet
Leblanc, Richard
Risse, Marie-Laure
Malinge, Laure
Schwab, Sandrine
Dimopoulos, Meletios A.
BLOOD, 2020, 136
[26] Carfilzomib and dexamethasone (Kd56) vs bortezomib and dexamethasone (Vd) in relapsed or refractory multiple myeloma (RRMM): Updated overall survival (OS), safety, and subgroup analysis of ENDEAVOR.
Orlowski, Robert Z.
Moreau, Philippe
Ludwig, Heinz
Rocafiguera, Albert Oriol
Chng, Wee Joo
Goldschmidt, Hartmut
Yang, Zhao
Kimball, Amy
Dimopoulos, Meletios A.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[27] A phase II study of daratumumab with weekly carfilzomib, pomalidomide, and dexamethasone in relapsed and refractory multiple myeloma.
Yee, Andrew J.
Nadeem, Omar
Rosenblatt, Jacalyn
Bianchi, Giada
O'Donnell, Elizabeth
Branagan, Andrew R.
Harrington, Cynthia C.
Agyemang, Emerentia A.
Gammon, Marilyn T.
Lively, Kathleen J.
Packer, Lisette A.
Bernstein, Zachary S.
Lyons, Rebecca T.
Riadi, Manal
Rowell, Sean M.
Mcvey, Cailin
Goguen, Amy C.
Horick, Nora K.
Richardson, Paul G.
Raje, Noopur S.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[28] Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in relapsed multiple myeloma patients with renal impairment: IKEMA subgroup analysis
Capra, Marcelo
Martin, Thomas
Moreau, Philippe
Baker, Ross
Pour, Ludek
Min, Chang-Ki
Leleu, Xavier
Mohty, Mohamad
Reinoso Segura, Marta
Turgut, Mehmet
LeBlanc, Richard
Risse, Marie-Laure
Malinge, Laure
Schwab, Sandrine
Dimopoulos, Meletios
HAEMATOLOGICA, 2022, 107 (06) : 1397 - 1409
[29] Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study(vol 396, 186, 2020)
Dimopoulos, M.
Quach, H.
Mateos, M-, V
Landgren, Ola
Leleu, Xavier
Siegel, David
Weisel, Katja
Yang, Hui
Klippel, Zandra
Zahlten-Kumeli, Anita
Usmani, Saad Z.
LANCET, 2020, 396 (10249): : 466 - 466
[30] Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS
Moreau, Philippe
Chari, Ajai
Oriol, Albert
Martinez-Lopez, Joaquin
Haenel, Mathias
Touzeau, Cyrille
Ailawadhi, Sikander
Besemer, Britta
de la Rubia Comos, Javier
Encinas, Cristina
Mateos, Maria-Victoria
Salwender, Hans
Rodriguez-Otero, Paula
Hulin, Cyrille
Karlin, Lionel
Sureda Balari, Anna
Bargay, Joan
Benboubker, Lotfi
Rosinol, Laura
Tarantolo, Stefano
Terebelo, Howard
Yang, Shiyi
Wang, Jianping
Nnane, Ivo
Qi, Ming
Kosh, Michele
Delioukina, Maria
Goldschmidt, Hartmut
BLOOD CANCER JOURNAL, 2023, 13 (01)

← 1 2 3 4 5 →